|Mr. Thomas Striepe||CEO, Pres, CFO & Exec. Director||82.62k||N/A||1962|
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and wound dressing spray under the Granulox brand. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.
Sangui Biotech International, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.